FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2622858197> ?p ?o ?g. }

• W2622858197 endingPage "50" @default.
• W2622858197 startingPage "41" @default.
• W2622858197 abstract "BACKGROUND: The rising costs of healthcare have forced policy makers to make choices, and new treatments are increasingly assessed in terms of the balance between additional costs and additional effects. The recent recognition that stenting has a major and long-lasting effect enhancing balloon PTCA procedure has made it imperative to compare in patients with multivessel disease the standard surgical procedure with multiple stenting in a large-scale multinational and multicenter approach (19 countries, 68 sites). METHODS: Selection and inclusion of patients is based on a consensus of the cardiac surgeon and interventional cardiologist on equal 'treatability' of patients by both techniques with analysis of clinical follow-up (event-free survival) on the short (30 days), medium (1 year), and long term (3 and 5 years) with analysis of cost-effectiveness and quality of life (EuroQol and SF-36). Of the entire trial, the primary null hypothesis which needs to be rejected is that there will be no difference in event-free survival or effectiveness (E), at 1 year and also that the direct and indirect costs (C) per event-free year are not different between surgery or stenting. For this to become significant with a power of 90% requires 1200 patients. Between April 97 and June 98, 1205 patients have been randomized with a monthly recruitment of 83 patients; the one year follow-up will thus be completed in June 1999. Expected costs, effects and cost-effectiveness ratio (CE ratio) for stents are: Stent: • high-cost estimate, 2 vessel disease (C 3 $19,297, E 3 81%, CE ratio 3 $23,876); 3 vessel disease (C 3 $24,566, E 3 81%, CE ratio 3 $30,397) low-cost estimate, 2 vessel disease (C 3 $16,638, E 3 81%, CE ratio 3 $20,586); 3 vessel disease (C 3 $20,456, E 3 81%, CE ratio 3 $25,322) Compared with CABG (C 3 $21,350, E 3 88%, CE ratio 3 $24,348) CONCLUSION: Clinically, stenting is not expected to be more effective than CABG, but should be cost-effective in both the 2- and 3-vessel disease groups when using the lower-cost estimate and in the 2 vessel group when using the higher-cost assumptions. (Int J Cardiovasc" @default.
• W2622858197 created "2017-06-15" @default.
• W2622858197 creator A5004247116 @default.
• W2622858197 creator A5012087697 @default.
• W2622858197 creator A5014665526 @default.
• W2622858197 creator A5025428537 @default.
• W2622858197 creator A5025643707 @default.
• W2622858197 creator A5029510800 @default.
• W2622858197 creator A5030343009 @default.
• W2622858197 creator A5033250422 @default.
• W2622858197 creator A5033359462 @default.
• W2622858197 creator A5036869816 @default.
• W2622858197 creator A5040135311 @default.
• W2622858197 creator A5048931664 @default.
• W2622858197 creator A5050035372 @default.
• W2622858197 creator A5051570036 @default.
• W2622858197 creator A5056291540 @default.
• W2622858197 creator A5061316225 @default.
• W2622858197 creator A5063792624 @default.
• W2622858197 creator A5066444956 @default.
• W2622858197 creator A5067879499 @default.
• W2622858197 creator A5082808804 @default.
• W2622858197 creator A5091032143 @default.
• W2622858197 creator A5091301686 @default.
• W2622858197 date "1999-01-01" @default.
• W2622858197 modified "2023-10-18" @default.
• W2622858197 title "The ARTS (Arterial Revascularization Therapies Study): Background, goals and methods" @default.
• W2622858197 cites W1994222210 @default.
• W2622858197 cites W2010514959 @default.
• W2622858197 cites W2020906145 @default.
• W2622858197 cites W2071686284 @default.
• W2622858197 cites W2074479676 @default.
• W2622858197 cites W2078823380 @default.
• W2622858197 cites W2140150910 @default.
• W2622858197 cites W2147869769 @default.
• W2622858197 cites W2165282467 @default.
• W2622858197 cites W2168667906 @default.
• W2622858197 cites W2324489407 @default.
• W2622858197 cites W2339621295 @default.
• W2622858197 doi "https://doi.org/10.1080/acc.2.1.41.50" @default.
• W2622858197 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12623386" @default.
• W2622858197 hasPublicationYear "1999" @default.
• W2622858197 type Work @default.
• W2622858197 sameAs 2622858197 @default.
• W2622858197 citedByCount "24" @default.
• W2622858197 countsByYear W26228581972012 @default.
• W2622858197 countsByYear W26228581972014 @default.
• W2622858197 crossrefType "journal-article" @default.
• W2622858197 hasAuthorship W2622858197A5004247116 @default.
• W2622858197 hasAuthorship W2622858197A5012087697 @default.
• W2622858197 hasAuthorship W2622858197A5014665526 @default.
• W2622858197 hasAuthorship W2622858197A5025428537 @default.
• W2622858197 hasAuthorship W2622858197A5025643707 @default.
• W2622858197 hasAuthorship W2622858197A5029510800 @default.
• W2622858197 hasAuthorship W2622858197A5030343009 @default.
• W2622858197 hasAuthorship W2622858197A5033250422 @default.
• W2622858197 hasAuthorship W2622858197A5033359462 @default.
• W2622858197 hasAuthorship W2622858197A5036869816 @default.
• W2622858197 hasAuthorship W2622858197A5040135311 @default.
• W2622858197 hasAuthorship W2622858197A5048931664 @default.
• W2622858197 hasAuthorship W2622858197A5050035372 @default.
• W2622858197 hasAuthorship W2622858197A5051570036 @default.
• W2622858197 hasAuthorship W2622858197A5056291540 @default.
• W2622858197 hasAuthorship W2622858197A5061316225 @default.
• W2622858197 hasAuthorship W2622858197A5063792624 @default.
• W2622858197 hasAuthorship W2622858197A5066444956 @default.
• W2622858197 hasAuthorship W2622858197A5067879499 @default.
• W2622858197 hasAuthorship W2622858197A5082808804 @default.
• W2622858197 hasAuthorship W2622858197A5091032143 @default.
• W2622858197 hasAuthorship W2622858197A5091301686 @default.
• W2622858197 hasConcept C112930515 @default.
• W2622858197 hasConcept C126322002 @default.
• W2622858197 hasConcept C141071460 @default.
• W2622858197 hasConcept C159110408 @default.
• W2622858197 hasConcept C168563851 @default.
• W2622858197 hasConcept C194828623 @default.
• W2622858197 hasConcept C23131810 @default.
• W2622858197 hasConcept C2778583881 @default.
• W2622858197 hasConcept C2779464278 @default.
• W2622858197 hasConcept C2779951463 @default.
• W2622858197 hasConcept C3019080777 @default.
• W2622858197 hasConcept C500558357 @default.
• W2622858197 hasConcept C71924100 @default.
• W2622858197 hasConceptScore W2622858197C112930515 @default.
• W2622858197 hasConceptScore W2622858197C126322002 @default.
• W2622858197 hasConceptScore W2622858197C141071460 @default.
• W2622858197 hasConceptScore W2622858197C159110408 @default.
• W2622858197 hasConceptScore W2622858197C168563851 @default.
• W2622858197 hasConceptScore W2622858197C194828623 @default.
• W2622858197 hasConceptScore W2622858197C23131810 @default.
• W2622858197 hasConceptScore W2622858197C2778583881 @default.
• W2622858197 hasConceptScore W2622858197C2779464278 @default.
• W2622858197 hasConceptScore W2622858197C2779951463 @default.
• W2622858197 hasConceptScore W2622858197C3019080777 @default.
• W2622858197 hasConceptScore W2622858197C500558357 @default.
• W2622858197 hasConceptScore W2622858197C71924100 @default.
• W2622858197 hasIssue "1" @default.
• W2622858197 hasLocation W26228581971 @default.

• next